MK 2206 dihydrochloride is a potent, orally active allosteric Akt inhibitor with IC50 of 5/12 nM for Akt1/Akt2 respectively.
MK 2206 shows 5-fold less potent against human Akt3 (IC50=65 nM).
MK 2206 synergistically inhibits cell proliferation of human cancer cell lines in combination with erlotinib or lapatinib in vitro.
MK 2206 suppresses the Akt phosphorylation that is induced by carboplatin and gemcitabine.
